News and Trends 9 Oct 2025
Are European biotech VCs under pressure to scale? Time to get pragmatic
As Asabys Partners has rolled Aliath Bioventures into its platform, it’s worth asking if European biotech VCs are under pressure to scale.
- Latest Posts
News and Trends 8 Oct 2025
Top biotech deals in September 2025
Discover the top biotech deals of September 2025, as four billion-dollar acquisitions took place and several licensing deals were signed.
Best in Biotech 7 Oct 2025
Six companies leading the mRNA revolution in biotechnology
Here are six mRNA biotechs that have raised funds in recent years to push their candidates ahead through preclinical and clinical trials.
In Depth 7 Oct 2025
AKIGAI takes EGFR inhibitors beyond cancer to treat neuropathic pain
Discover how AKIGAI’s EGFR inhibitors may redefine neuropathic pain therapy and offer hope for complex regional pain syndrome (CRPS).
In Depth 3 Oct 2025
The biggest biotech funding rounds in September 2025
uniQure, Dianthus Therapeutics, and Mineralys Therapeutics bagged the biggest biotech funding rounds overall in September 2025.
Podcast 3 Oct 2025
Raising money in uncertain times: how Splice Bio secured $135 million for its gene therapy play
This week, we discussed funding with Gerard Caelles, Chief Business Office of Splice Bio, a company that just closed a $135 million series B round.
ADVERTISEMENT
ADVERTISEMENT
News and Trends 1 Oct 2025
Merck backs out of Britain: is the U.K. struggling to retain its life sciences sector?
Merck’s decision to back out of its $1 billion expansion comes as U.K. investments in life sciences declines.
News and Trends 1 Oct 2025
Asthma study suggests lung scarring may be reversible
Find out about this new study that suggest that the lung scarring that severe asthma can cause could be reversible.
Best in Biotech 30 Sep 2025
CRISPR technology’s next wave: Ten companies to watch in 2025
Driven by CASGEVY’s success, the CRISPR field is experiencing substantial growth with a new wave of companies.
News and Trends 29 Sep 2025
First-ever approval for Barth Syndrome treatment: what does this mean for ultra-rare disease therapeutics?
FDA approval for Stealth BioTherapeutics’ elamipretide has been a long time coming. What does this mean for other ultra-rare disease companies?
Destination BIOSPAIN 2025: What you need to know about Spain’s flagship event for biotech
BIOSPAIN 2025 returns to Barcelona, bringing 2,200+ biotech professionals for networking, collaborations, and industry insights.
In Depth 26 Sep 2025
Can biotechnology reduce animal testing in medicine?
Animal testing is crucial for measuring the efficacy and safety of new treatments. It is also a step that everyone would like to avoid as much as possible for economic, regulatory, and ethical reasons. But what are the alternatives, and can they really reduce the use of animals in drug development? Before drug developers let […]
ADVERTISEMENT
